COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
12 Months Ended | |
|---|---|---|
Jun. 10, 2026 |
Jun. 30, 2026 |
|
| Loss Contingencies [Line Items] | ||
| New shares value | ||
| Over-Allotment Option [Member] | ||
| Loss Contingencies [Line Items] | ||
| Number of units issued | 1,500,000 | |
| Stock Issued During Period, Shares, New Issues | 170,000 | |
| New shares value | $ 280,500 | |
| IPO [Member] | ||
| Loss Contingencies [Line Items] | ||
| Number of units issued | 11,500,000 | |
| Cash underwriting discounts | 517,500 | |
| Deferred underwriting commissions | $ 517,500 | $ 4,025,000 |
| Maximum [Member] | Over-Allotment Option [Member] | ||
| Loss Contingencies [Line Items] | ||
| Number of units issued | 1,500,000 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|